Enzyme replacement therapy built the Gaucher type 1 market over three decades — now oral eliglustat competes as the only first-line oral therapy, and the mechanism contest is ERT versus substrate reduction.
Gaucher disease type 1 (non-neuronopathic) accounts for more than 90% of Gaucher cases and is the only form with disease-modifying therapy addressing its visceral, hematologic, and skeletal manifestations. The US market splits by mechanism. Enzyme replacement therapy (ERT) replaces deficient acid β-glucosidase and is delivered by intravenous infusion: imiglucerase (Cerezyme, Sanofi/Genzyme, approved May 1994), velaglucerase alfa (VPRIV, Takeda, March 2010), and taliglucerase alfa (Elelyso, Pfizer, May 2012). Substrate reduction therapy (SRT) is oral and inhibits glucosylceramide synthase to lower substrate load: eliglustat (Cerdelga, Sanofi, 2014) and miglustat (Zavesca, Actelion/Janssen, 2003).
The commercial contest is route and line of therapy. Eliglustat is the only first-line oral therapy for adults with Gaucher type 1, but its label restricts use to CYP2D6 extensive, intermediate, or poor metabolizers identified by an FDA-cleared test — a genotype gate absent from ERT. In the ENGAGE trial, previously untreated patients on eliglustat had a 30% placebo-adjusted reduction in spleen volume, a 1.22 g/dL hemoglobin increase, and a 41% platelet rise at 9 months (JAMA 2015). Miglustat, approved a decade earlier, is positioned narrowly — for mild-to-moderate type 1 patients for whom ERT is not a therapeutic option — and now faces generic competition. The result is a mature, high-cost market where the strategic question is IV incumbency versus oral convenience.
FDA-approved Gaucher disease type 1 therapies — United States, 2026
| Drug (Brand / INN) | Mechanism | Company | Route | US Approval | Key Trial / Positioning |
|---|---|---|---|---|---|
| Cerezyme (imiglucerase) | Enzyme replacement (ERT) | Sanofi / Genzyme | IV infusion | May 1994 | First ERT; standard of care; dosing 2.5–60 U/kg |
| VPRIV (velaglucerase alfa) | Enzyme replacement (ERT) | Takeda | IV infusion | Mar 2010 | Gene-activated human enzyme; every-other-week infusion |
| Elelyso (taliglucerase alfa) | Enzyme replacement (ERT) | Pfizer / Protalix | IV infusion | May 2012 | Plant-cell-expressed enzyme; adults with type 1 |
| Cerdelga (eliglustat) | Substrate reduction (SRT), oral | Sanofi / Genzyme | Oral capsule | Aug 2014 | ENGAGE: spleen −30% vs placebo; only first-line oral; CYP2D6-gated |
| Zavesca (miglustat) | Substrate reduction (SRT), oral | Actelion / Janssen | Oral capsule | Jul 2003 | Mild–moderate type 1 when ERT not an option; now generic |
Sources: FDA Drugs@FDA (BLA020367, BLA022575, BLA022458, NDA205494, NDA021348); ENGAGE, JAMA 2015 (PMID 25688781); Cerdelga and Zavesca FDA prescribing information.
What this brief answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- ERT vs SRT mechanism and the IV-versus-oral split
- efficacy across ENGAGE and ENCORE
- dosing and infusion burden by agent
- where line of therapy separates first-line oral eliglustat from the rest
Delivers
- The CYP2D6 metabolizer eligibility gate and its effect on addressable population
- switching considerations in a chronic infused market
- positioning against three decades of ERT incumbency
Delivers
- Annual cost by agent
- Part B infusion routing vs Part D oral routing
- generic miglustat's low-end anchor
- preferred-ERT designation as a payer lever
Custom brief delivered in 72 hours.
Commission This BriefWhat's inside
- Five FDA-approved Gaucher type 1 therapies split into three IV enzyme-replacement agents and two oral substrate-reduction agents
- Type 1 accounts for more than 90% of Gaucher cases and is the only form with disease-modifying therapy, setting the addressable market
- Imiglucerase (1994), velaglucerase alfa (2010) and taliglucerase alfa (2012): three IV enzyme-replacement agents from Sanofi/Genzyme, Takeda, and Pfizer/Protalix
- Eliglustat (2014) and miglustat (2003): the two oral substrate-reduction agents and their distinct label positioning
- In ENGAGE, previously untreated patients on eliglustat saw a 30% placebo-adjusted spleen-volume reduction, 1.22 g/dL hemoglobin increase, and 41% platelet rise at 9 months
- Eliglustat's label restricts use to CYP2D6 extensive, intermediate or poor metabolizers identified by an FDA-cleared test, a genotype gate absent from any ERT agent
- Cerezyme has anchored the ERT market since 1994, three decades of incumbency that any oral or newer IV agent must displace
- Miglustat is positioned narrowly for mild-to-moderate type 1 patients for whom ERT is not a therapeutic option, and now faces generic competition
- IV enzyme-replacement agents route through the medical benefit (Part B) while oral eliglustat and miglustat route through the pharmacy benefit (Part D)
- Generic miglustat sets the market's low-cost anchor, while payers use preferred-ERT designation among the three infused agents as a negotiating lever
- The bar next-generation Gaucher therapies must clear: ENGAGE's 30% spleen-volume reduction without ERT's IV infusion burden or eliglustat's CYP2D6 genotype gate
- Where three decades of ERT incumbency and a genotype-restricted oral option leave room for a next mechanism to broaden first-line eligibility
Included with every brief
How AXLRx builds this brief
Prepared by MoatRx analysts.
Every AXLRx brief is built from primary regulatory sources (FDA Drugs@FDA, ClinicalTrials.gov), peer-reviewed literature, and live payer and HTA documentation — not secondary summaries, market-research reports, or unverified estimates. Findings are independently verified before inclusion; if a figure cannot be sourced to a live record, it does not ship.
US Gaucher Disease Competitive Intelligence sources: FDA Drugs@FDA approval records (BLA020367 imiglucerase, BLA022575 velaglucerase alfa, BLA022458 taliglucerase alfa, NDA205494 eliglustat, NDA021348 miglustat), the ENGAGE randomized trial (JAMA 2015, PMID 25688781), and the Cerdelga and Zavesca FDA prescribing information.
- Approval status, routes and applicants verified against FDA Drugs@FDA (BLA020367, BLA022575, BLA022458, NDA205494, NDA021348)
- Eliglustat efficacy verified against the ENGAGE randomized trial, JAMA 2015 (PMID 25688781)
- Eliglustat first-line status and CYP2D6 metabolizer restriction verified against the Cerdelga FDA prescribing information
- Miglustat second-line positioning verified against the Zavesca FDA prescribing information
Frequently asked questions
Commission this brief
AXLRx delivers US Gaucher disease type 1 competitive intelligence built for pharma and biotech commercial, access, and medical affairs teams. Custom brief in 72 hours.
Use the intake form to specify your indication, geography, and commercial question.
AXLRx analyst confirms scope, comparators, and delivery format.
Research-verified brief in 72 hours with optional analyst readout.